Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial

Simply Wall St.02-28

Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614889723?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-28 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614889723","market":"hk","top_or_hot":-1,"title":"Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial","media":"Simply Wall St.","content":"<div>\n<p>Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 13:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into","article_id":"2614889723","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614889723","pubTimestamp":1772256516,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment.\nThis shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors.\nNext, we’ll examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio(NUVB)将Safusidenib推进至3期脑癌试验后股价上涨8.6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1.5},"content_text":"Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment. This shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors. Next, we’ll examine how advancing safusidenib into a Phase 3 registrational trial could reshape Nuvation Bio’s investment narrative and risk profile. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementNuvation Bio Investment Narrative RecapTo own Nuvation Bio, you need to believe IBTROZI can sustain its role in ROS1 positive lung cancer while safusidenib matures into a viable second pillar in IDH1 mutant glioma. The SIGMA protocol amendment into a larger Phase 3 registrational trial sharpens that thesis but also reinforces the timing risk, as meaningful safusidenib data still sit several years away and the business remains heavily reliant on IBTROZI and external financing in the meantime. Among recent events, the expanded Phase 3 SIGMA design is most relevant here because it directly affects both the potential scale and timing of safusidenib as a future revenue driver. Tripling enrollment to 300 high risk patients across grades 2 to 4 IDH1 mutant glioma broadens the commercial opportunity if successful, but it may also extend trial execution complexity and prolong the period before investors get clarity on whether safusidenib can truly support Nuvation’s long term earnings profile alongside IBTROZI. Yet, beneath this upside story, investors also need to be aware that the longer trial timeline could leave Nuvation more exposed to... Read the full narrative on Nuvation Bio (it's free!)Nuvation Bio's narrative projects $427.2 million revenue and $5.2 million earnings by 2028. This requires 151.8% yearly revenue growth and about a $222.7 million earnings increase from -$217.5 million today.Uncover how Nuvation Bio's forecasts yield a $10.25 fair value, a 73% upside to its current price.Exploring Other PerspectivesNUVB 1-Year Stock Price Chart Before this safusidenib Phase 3 expansion, the most bullish analysts were already modeling about US$522.3 million of revenue and US$38.0 million of earnings by 2028, which is a far more optimistic path than the consensus view built around slower trial timelines and commercial risk for IBTROZI, reminding you that opinions on Nuvation’s future can differ widely and may shift again as this new trial design plays out.Explore 7 other fair value estimates on Nuvation Bio - why the stock might be worth less than half the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Nuvation Bio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nuvation Bio's overall financial health at a glance.Searching For A Fresh Perspective?Every day counts. These free picks are already gaining attention. See them before the crowd does:Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Uncover the next big thing with 30 elite penny stocks that balance risk and reward.The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614889723","isCrawlerRequest":true}